🇺🇸 FDA
Pipeline program

Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

ICRG0201

Phase 2 small_molecule active

Quick answer

Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) for Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials